Annis Gardner Whiting Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1	Closed	-$242	–	1217
2025 Q2	$242	Buy	+1	New	+$236	﹤0.01%	1258
2025 Q1	–	Sell	-1	Closed	-$329	–	755
2024 Q4	$329	Buy	+1	New	+$339	﹤0.01%	754
2024 Q3	–	Sell	-1	Closed	-$274	–	766
2024 Q2	$274	Hold	1	–	–	﹤0.01%	932
2024 Q1	$346	Buy	+1	New	+$329	﹤0.01%	917

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's BIO Position: Q3 2025 in Review

Annis Gardner Whiting Capital Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2025, closing a stake of 1 share — an estimated $242 sold.

Annis Gardner Whiting Capital Advisors first reported a position in BIO in Q1 2024 and held it in 4 quarters. The position peaked at $346 in Q1 2024. 397 funds tracked by Wall St. Rank hold BIO as of Q3 2025.

Annis Gardner Whiting Capital Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q3 2025 after selling out during the quarter.
Annis Gardner Whiting Capital Advisors sold 1 Bio-Rad Laboratories Class A share in Q3 2025, an estimated $242.
Annis Gardner Whiting Capital Advisors first reported a position in Bio-Rad Laboratories Class A in Q1 2024 and held it in 4 quarters.
Annis Gardner Whiting Capital Advisors's Bio-Rad Laboratories Class A position peaked at $346 in Q1 2024.
397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2025.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q3 2025, filed 3 Nov 2025.